Rice Hall James & Associates LLC Increases Position in Taysha Gene Therapies, Inc. $TSHA

Rice Hall James & Associates LLC lifted its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 53.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,944,671 shares of the company’s stock after buying an additional 674,026 shares during the period. Rice Hall James & Associates LLC’s holdings in Taysha Gene Therapies were worth $8,693,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Vestal Point Capital LP increased its position in Taysha Gene Therapies by 150.0% in the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after acquiring an additional 8,250,000 shares during the period. Goldman Sachs Group Inc. raised its stake in Taysha Gene Therapies by 2.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock valued at $75,310,000 after acquiring an additional 309,031 shares during the last quarter. Vanguard Group Inc. raised its stake in Taysha Gene Therapies by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock valued at $72,973,000 after acquiring an additional 418,192 shares during the last quarter. Octagon Capital Advisors LP lifted its position in Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after acquiring an additional 1,892,500 shares during the period. Finally, State Street Corp lifted its position in Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after acquiring an additional 3,553,619 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TSHA. BMO Capital Markets lifted their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Bank of America increased their price target on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Robert W. Baird increased their price target on Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $12.77.

Insiders Place Their Bets

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider owned 936,410 shares of the company’s stock, valued at $5,843,198.40. This represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is owned by corporate insiders.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $5.52 on Friday. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average is $5.97 and its two-hundred day moving average is $5.36. Taysha Gene Therapies, Inc. has a 12-month low of $2.53 and a 12-month high of $7.30. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -14.53 and a beta of 1.17.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Research analysts expect that Taysha Gene Therapies, Inc. will post -0.49 EPS for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.